Xenothera SAS
- Country
- 🇫🇷France
- Ownership
- Holding
- Established
- 2014-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.xenothera.com
Clinical Trials
6
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Polyspecific Antibodies in Lymphoproliferative T-cell Disorders
- First Posted Date
- 2024-07-11
- Last Posted Date
- 2025-06-22
- Lead Sponsor
- Xenothera SAS
- Target Recruit Count
- 54
- Registration Number
- NCT06495723
- Locations
- 🇮🇹
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Lombardia, Italy
🇫🇷CHU de Caen, Caen, France
🇫🇷CHU de Clermont-Ferrand, Clermont-Ferrand, France
FIH XON7 in Advanced/Metastatic Solid Tumors
- First Posted Date
- 2023-12-04
- Last Posted Date
- 2025-06-22
- Lead Sponsor
- Xenothera SAS
- Target Recruit Count
- 255
- Registration Number
- NCT06154291
- Locations
- 🇫🇷
Institut Bergonié, Bordeaux, France
🇧🇪Institut Jules Bordet, Anderlecht, Belgium
🇫🇷Centre Léon Bérard, Lyon, France
A First-in-Human Study With XAB05 in Healthy Subjects
- Conditions
- Infection, Bacterial
- First Posted Date
- 2022-04-01
- Last Posted Date
- 2022-08-12
- Lead Sponsor
- Xenothera SAS
- Target Recruit Count
- 25
- Registration Number
- NCT05307406
- Locations
- 🇳🇱
QPS Netherlands B.V., Groningen, Netherlands
Efficacy and Safety of XAV-19 for the Treatment of Moderate-to-severe COVID-19
- First Posted Date
- 2021-06-16
- Last Posted Date
- 2023-01-23
- Lead Sponsor
- Xenothera SAS
- Target Recruit Count
- 290
- Registration Number
- NCT04928430
- Locations
- 🇧🇬
Multiprofile Hospital for Active Treatment " St. Ekaterina" - Dimitrovgrad - EOOD, COVID Departement, Dimitrovgrad, Bulgaria
🇧🇬University Multiprofile Hospital for Active Treatment - Plovdiv - AD, COVID Departement, Plovdiv, Bulgaria
🇧🇬Complex Oncological Center - Ruse Ltd, COVID Departement, Ruse, Bulgaria
First in Human Study: LIS1, an Induction Treatment in Kidney Transplanted Patients
- Conditions
- Kidney Transplant
- First Posted Date
- 2020-06-16
- Last Posted Date
- 2022-08-17
- Lead Sponsor
- Xenothera SAS
- Target Recruit Count
- 10
- Registration Number
- NCT04431219
- Locations
- 🇨🇿
Institut klinické a experimentální medicíny, Praha 4, Czechia